arrow
A

Aaron R. Hansen

University of Toronto
H指数:58
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR)

早期剂量探索性肿瘤临床试验中患者报告结局的分析与可视化实用工具包与建议(OPTIMISE-AR)

2026-03-170
PRE
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

Binimetinib和encorafenib用于非-V600E BRAF突变晚期实体瘤的治疗:来自BEAVER II期试验的结果

2026-01-030
OAAI
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)

在接受基于免疫治疗的一线治疗后转移性肾细胞癌(mRCC)中的患者流失率:来自国际mRCC数据库联盟(IMDC)的结果

2026-01-010
PRE
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer

去势抵抗性前列腺癌中AR位点突变的谱系和临床分级

2025-10-270
OAAI
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab

细胞外DNA中的T细胞受体库作为接受帕博利珠单抗治疗患者肿瘤浸润细胞的替代标志物

2025-08-270
PREAI
Development, Validation, and Valuation of a Head and Neck Cancer-Specific Health Utility Instrument (HNC-8D) A Head and Neck Cancer International Group Collaborative Study

头颈癌特异性健康效用量表(HNC-8D)的开发、验证与价值评估:一项头颈癌国际协作组合作研究

2025-06-010
PRE
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

帕博利珠单抗在微卫星高度不稳定/错配修复缺陷(MSI-H/dMMR)和非微卫星高度不稳定/非错配修复缺陷(non-MSI-H/non-dMMR)晚期子宫内膜癌中的疗效:KEYNOTE-158研究II期结果

2025-02-012
PRE
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
2025-01-070
OAAI
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma

头颈部鳞状细胞癌患者免疫细胞因子Simlukafusp Alfa (FAP-IL2v) 联合西妥昔单抗的Ib期研究

2024-10-180
OAAI
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable

推进以患者为中心的护理: 在早期临床试验中整合患者报告的结果进行耐受性评估-来自专家虚拟圆桌会议的见解

2024-10-010
OAAI
TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations
2024-10-010
PRE
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
2024-09-012
PRE
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial (vol 42, pg 145, 2024)

CXCR2拮抗剂navarixin联合pembrolizumab治疗晚期实体瘤: 一项2期随机试验 (第42卷,145页,2024)

2024-05-200
OAAI
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study
2024-05-071
PRE